Rare Disease Report
Patients & Caregivers

The Safety and Efficacy of Ruxolitinib in Polycythemia Vera

SEPTEMBER 13, 2016
Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas describes the RESPONSE Study showing the efficacy of ruxolitinib in patients with polycythemia vera refractory to hydroxyurea.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.